If you’ve been told to “manage” cancer pain with morphine and patience, I want you to know there’s more to the conversation. I co-authored the American Society of Pain and Neuroscience’s Best Practices and Guidelines for Cancer-Associated Pain, and I’ll tell you the same thing I tell every patient who walks into my Hoffman Estates office with a cancer diagnosis: the interventional toolbox is bigger than most oncology clinics let on.
This isn’t about replacing your oncologist. It’s about getting you in front of a pain physician early — not at the end, when the options have narrowed.
The first thing most patients don’t know
Cancer pain is not one thing. It’s at least three things, often layered together:
- Pain from the tumor itself — pressing on bone, organ, or nerve.
- Pain from treatment — chemotherapy-induced neuropathy, post-surgical scar pain, radiation-related nerve damage.
- Pain from the patient’s body adapting — muscle spasm, joint pain, posture changes that didn’t exist before the diagnosis.
Each of these responds to different interventions. A morphine increase that helps the first two might do nothing for the third. That’s why the guideline’s first recommendation is: get a multidisciplinary evaluation, not a single-drug answer.
What the interventional options actually look like
Here’s what I do in my practice for cancer-associated pain, drawn straight from the ASPN guideline our committee built:
Targeted nerve blocks and neurolysis. When a tumor is pressing on a specific nerve plexus — most commonly the celiac plexus for upper abdominal cancers like pancreatic — a single injection of a precise nerve-blocking medication can drop pain by 50–80% and hold for months. This is one of the highest-impact, lowest-risk interventions in oncology pain medicine, and it’s still wildly underused.
Intrathecal drug delivery. A small pump implanted under the skin delivers pain medication directly to the spinal fluid, bypassing the bloodstream. The dose is roughly 1/300th of an oral equivalent for the same effect. That means dramatically fewer side effects — less drowsiness, less nausea, less constipation. For patients who can’t tolerate oral opioids, or who want to drive their grandkids to school in the morning instead of sleeping through it, this can be life-changing.
Spinal cord stimulation and DRG stimulation. For cancer survivors with chronic post-treatment neuropathic pain — chemo neuropathy, post-mastectomy pain, post-thoracotomy pain — neuromodulation devices can deliver targeted relief without medication. The recovery curve is measured in weeks, not years.
Vertebral augmentation (kyphoplasty). When cancer has weakened a vertebra and caused a compression fracture, kyphoplasty stabilizes the bone in a 30-minute outpatient procedure. Patients often walk in bent over and walk out standing straight.
Radiotherapy and surgical techniques that work alongside the procedures above — and increasingly, AI-assisted treatment planning that I’ve also written about in a 2024 Journal of Pain Research paper.
Who should ask about this
If you or someone you love is currently dealing with cancer pain that isn’t well-controlled — meaning pain that’s interfering with sleep, eating, mood, or activity — you should ask whoever’s treating your cancer this exact question:
“Should I see an interventional pain physician now, while we still have options on the table?”
That word “now” matters. The guideline is specific: the earlier the referral, the more options remain. Late referrals are limited by tumor location, body deconditioning, and time.
What I tell my patients
Cancer is hard. Cancer pain shouldn’t be the part you remember most. The interventional toolkit our ASPN committee codified in 2021 was built precisely to give patients more options, earlier — not as a hand-off when nothing else worked.
If you’re in the Chicago suburbs and you’d like to talk through your cancer-pain options, my office is in Hoffman Estates and we accept oncology referrals from across the region. Call (847) 981-3630 or request an appointment online.
The full ASPN guideline is publicly available on PubMed — share it with your oncologist if it helps the conversation.